| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Sinovac Biotech, Ltd$6.47
-0.02 (-0.31%)
B 65Pipeline Score Undervalued Pharma · Clinical
Market Cap
464.94 M
EPS
-
P/E Ratio
-
Value Trade
53.43 K
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
8.23 K
52 Week Range
-
% held by Insiders
-
% held by Institutions
-
Enterprise Value
-
Total Shares
99.38 M
Short %
0.44 %
Float Shares
18.88 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
B65
Pipeline Score $4.5B
Pipeline ValueUndervalued
Valuation Signal30
Drugs Scored9.6x
rNPV / MCap Top 92%
Micro Cap (rank 73 of 905)
Percentile RankSinovac Biotech, Ltd holds a solid B-grade pipeline (65/100), with $14.8B risk-adjusted pipeline value, led by Sinovac PCV13 in Pneumococcal Infectious Diseases (Phase 3), across $106B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sinovac PCV13 Monoclonal antibody | Pneumococcal Infectious Diseases | Phase 3 | NCT07593924 | 57% | $3.8B | NOT YET_RECRUITING | 500 | VERY_FAST | C (57) | Jul 1, 2027 | - | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in SVA
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Sinovac Biotech, Ltd (SVA) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
SVA
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
SVA
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
SVA
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
SVA Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
SVA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-SVA
Jun 15, 2026SINOVAC Regained Compliance With the Nasdaq Global Market’s Listing Requirements
SINOVAC has regained compliance with the Nasdaq Global Market's listing requirements, indicating a positive step for the company. This compliance suggests that SINOVAC has met the necessary financial and operational standards set by Nasdaq. The news may impact investor confidence and market perception positively.
Read more →-SVA
Jun 5, 2026SINOVAC Reports Unaudited and Unreviewed Second Half of 2025 Financial Results and Files 2025 Annual Report on Form 20-F
SINOVAC has reported its unaudited and unreviewed financial results for the second half of 2025. The company has also filed its 2025 Annual Report on Form 20-F. However, the unaudited nature of the results may raise concerns among investors regarding the reliability of the financial data.
Read more →-SVA
May 29, 2026SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report
SINOVAC has been notified by Nasdaq about the late filing of its 2025 Annual Report. This notification indicates potential compliance issues that may affect the company's standing on the exchange. Investors may view this delay as a negative signal regarding the company's financial reporting practices.
Read more →-SVA
May 21, 2026SINOVAC Announces Extension of Deadline to Submit Payment Instructions for Previously Declared Special Cash Dividend
SINOVAC has announced an extension of the deadline for shareholders to submit payment instructions for its previously declared special cash dividend. This decision aims to ensure that all eligible shareholders have adequate time to participate in the dividend distribution. The announcement reflects the company's commitment to shareholder engagement and transparency.
Read more →-SVA
May 8, 2026SINOVAC Reports Unaudited First Half of 2025 Financial Results
SINOVAC has reported its unaudited financial results for the first half of 2025. The report lacks detailed insights, leading to concerns about the company's financial health. Investors may find the absence of comprehensive data troubling as it could impact future business decisions.
Read more →-SVA
Apr 30, 2026SINOVAC Files Annual Report on Form 20-F for the Fiscal Year 2024
Sinovac Biotech Ltd. has filed its annual report on Form 20-F for the fiscal year 2024 with the SEC. The report highlights the company's extensive portfolio of vaccines and its commitment to combating infectious diseases. Sinovac continues to innovate and expand its global presence, aiming to enhance vaccine development and accessibility.
Read more →-SVA
Jan 22, 2026SINOVAC Announces Nasdaq Hearings Panel Grants Continued Listing
Sinovac Biotech Ltd. has received approval from the Nasdaq Hearings Panel to continue its listing, contingent upon meeting specific financial filing requirements by May 11, 2026. The company is collaborating with Zhonghua Certified Public Accountants LLP to ensure compliance with Nasdaq rules and complete necessary audits. Sinovac remains focused on maintaining its commitment to regulatory obligations.
Read more →-SVA
Jan 5, 2026Sinovac Receives Nasdaq Notification Regarding Late Filing of 2025 Half-Year Report
Sinovac Biotech Ltd. has received a notification from Nasdaq regarding its late filing of the 2025 half-year report. The company is scheduled to present its case to the Nasdaq Hearings Panel on January 8, 2026, in an effort to maintain its listing. This follows a previous delisting determination received in November 2025.
Read more →Competitive Position
How SVA ranks across every disease it competes inCompetitive Position is a premium feature
See how SVA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial